Cigna rolls out new plan to fully cover multi-million dollar gene therapies - (NASDAQ via NewsPoints Desk)

  • Cigna announced a plan to fully cover expensive gene therapies, as reported NASDAQ Thursday.

  • The news comes as Novartis and Spark Therapeutics have received criticism over high prices of their gene therapies Zolgensma and Luxturna, respectively

  • The news also follows a report that Cigna's Express Scripts unit had entered into negotiations last year to become the exclusive distributor of gene therapies for select companies.

  • Guggenheim analyst Whitney Ijem suggested that the addressable market for ongoing gene therapy development programmes could be as large as 2.4 billion patients globally, with further growth anticipated.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.